Company Description
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease.
In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity.
Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jul 18, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 290 |
| CEO | R. Struthers |
Contact Details
Address: 6055 Lusk Boulevard San Diego, California 92121 United States | |
| Phone | 858 450 6464 |
| Website | crinetics.com |
Stock Details
| Ticker Symbol | CRNX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001658247 |
| CUSIP Number | 22663K107 |
| ISIN Number | US22663K1079 |
| Employer ID | 26-3744114 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. R. Scott Struthers Ph.D. | Founder, President, Chief Executive Officer and Director |
| Dr. Stephen F. Betz Ph.D. | Founder and Chief Scientific Officer |
| Jeff E. Knight | Chief Operating Officer |
| Dr. Alan S. Krasner M.D. | Chief Endocrinologist |
| Gayathri Diwakar | Head of Investor Relations |
| Garlan Adams | General Counsel and Corporate Secretary |
| Adriana Cabre M.B.A. | Chief Human Resources Officer |
| Kevin Capps | Head of Intellectual Property |
| Chris Robillard M.B.A. | Chief Business Officer |
| Dr. Dana Pizzuti M.D. | Chief Medical and Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 17, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 16, 2024 | 8-K | Current Report |